Mir-17~92 cooperates with RB pathway mutations to promote retinoblastoma

174Citations
Citations of this article
135Readers
Mendeley users who have this article in their library.

Abstract

The miR-17~92 cluster is a potent microRNA-encoding oncogene. Here, we show that miR-17~92 synergizes with loss of Rb family members to promote retinoblastoma. We observed miR-17~92 genomic amplifications in murine retinoblastoma and high expression of miR-17~92 in human retinoblastoma. While miR-17~92 was dispensable for mouse retinal development, miR-17~92 overexpression, together with deletion of Rb and p107, led to rapid emergence of retinoblastoma with frequent metastasis to the brain. miR-17~92 oncogenic function in retino-blastoma was not mediated by a miR-19/PTEN axis toward apoptosis suppression, as found in lymphoma/ leukemia models. Instead, miR-17~92 increased the proliferative capacity of Rb/p107-deficient retinal cells. We found that deletion of Rb family members led to compensatory up-regulation of the cyclin-dependent kinase inhibitor p21Cip1. miR-17~92 overexpression counteracted p21Cip1 up-regulation, promoted proliferation, and drove retinoblastoma formation. These results demonstrate that the oncogenic determinants of miR-17~92 are context-specific and provide new insights into miR-17~92 function as an RB-collaborating gene in cancer.

Cite

CITATION STYLE

APA

Conkrite, K., Sundby, M., Mukai, S., Michael Thomson, J., Mu, D., Hammond, S. M., & MacPherson, D. (2011). Mir-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes and Development, 25(16), 1734–1745. https://doi.org/10.1101/gad.17027411

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free